Table 1

Association of Kif11 and PCNA expression with clinical characteristics and selected biological markers of CCRCC

CharacteristicnKif11 expression (%)PCNA expression (%)
HighLow or noneχ2 P valueHighLow or noneχ2 P value
Age (years)0.2450.6210.2000.655
 ≤607045 (64.29)25 (35.71)40 (57.14)30 (42.9)
 >607344 (60.27)29 (39.73)39 (53.42)34 (46.6)
Location0.6320.4260.1100.740
 Left7645 (59.21)31 (40.79)41 (53.95)35 (46.1)
 Right6744 (65.67)23 (34.33)38 (56.72)29 (43.3)
Gender1.4830.2230.4140.520
 Male10059 (59.00)41 (41.00)57 (57.00)43 (43.0)
 Female4330 (69.77)13 (30.23)22 (51.16)21 (48.8)
Tumour size (cm)2.4830.1151.5260.217
 ≤77039 (55.71)31 (44.29)35 (50.00)35 (50.0)
 >77350 (68.49)23 (31.51)44 (60.27)29 (39.7)
Nuclear grade7.7370.0216.5130.039
 G15225 (48.08)27 (51.92)22 (42.31)30 (57.69)
 G26141 (67.21)20 (32.79)36 (59.02)25 (40.98)
 G3–43023 (76.67)7 (23.33)21 (70.00)9 (30.00)
TNM stage22.55<0.00113.0300.001
 Ⅰ5722 (38.60)35 (61.40)21 (36.84)36 (63.16)
 Ⅱ6047 (78.33)13 (21.67)40 (66.67)20 (33.33)
 Ⅲ+Ⅳ2620 (76.92)6 (23.08)18 (69.23)8 (30.77)
  • CCRCC, clear cell renal cell carcinoma; Kif11, kinesin family member 11; PCNA, proliferating cell nuclear antigen.